US equities
|
SPCX
$168.37
▲+5.92%
NVDA
$237.36
▲+1.46%
MU
$1,066.37
▼-0.79%
TSLA
$378.75
▲+2.20%
MSFT
$525.51
▲+1.54%
SNDK
$1,715.00
▼-0.29%
INTC
$117.23
▼-1.76%
META
$743.24
▲+2.08%
SPCX
$168.37
▲+5.92%
NVDA
$237.36
▲+1.46%
MU
$1,066.37
▼-0.79%
TSLA
$378.75
▲+2.20%
MSFT
$525.51
▲+1.54%
SNDK
$1,715.00
▼-0.29%
INTC
$117.23
▼-1.76%
META
$743.24
▲+2.08%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Verve Therapeutics, Inc. - Common Stock
(NQ:
VERV
)
11.13
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Jul 24, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Verve Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
12
13
Next >
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Verve Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – VERV
September 17, 2024
From
The Rosen Law Firm PA
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against WEBTOON, Verve, and Ardelyx and Encourages Investors to Contact the Firm
September 13, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Verve Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – VERV
September 13, 2024
From
The Rosen Law Firm PA
Via
GlobeNewswire
Faruqi & Faruqi Reminds Verve Therapeutics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 28, 2024 - VERV
September 13, 2024
From
Faruqi & Faruqi LLP
Via
GlobeNewswire
Shareholder Rights Attorneys Robbins LLP Reminds VERV Stockholders of the Opportunity to Lead the Verve Therapeutics, Inc. Class Action
September 10, 2024
From
Robbins LLP
Via
Business Wire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against WEBTOON, Verve, and Ardelyx and Encourages Investors to Contact the Firm
September 09, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
INVESTOR ALERT: Shareholder Class Action Lawsuit Filed Against Verve Therapeutics, Inc. (NASDAQ: VERV); Investors with Losses Encouraged to Discuss Their Options with Counsel
September 09, 2024
From
DiCello Levitt LLP
Via
GlobeNewswire
VERV SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Verve Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
September 09, 2024
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Verve Therapeutics
September 06, 2024
From
Faruqi & Faruqi LLP
Via
GlobeNewswire
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Verve Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – VERV
September 05, 2024
From
The Rosen Law Firm PA
Via
GlobeNewswire
VERV Class Action Notice: Robbins LLP Reminds Stockholders of the Lead Plaintiff Deadline in the Verve Therapeutics, Inc. Class Action
September 04, 2024
From
Robbins LLP
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against CAE, Verve, and MongoDB and Encourages Investors to Contact the Firm
September 03, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
September 03, 2024
From
Verve Therapeutics
Via
GlobeNewswire
VERV Investors Have Opportunity to Lead Verve Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
September 03, 2024
From
Schall Law
Via
GlobeNewswire
REMINDER – Verve Therapeutics, Inc. Investor Alert: Robbins LLP Reminds Shareholders of the VERV Class Action Lawsuit
September 03, 2024
From
Robbins LLP
Via
Business Wire
VERVE THERAPEUTICS, INC. (NASDAQ: VERV) INVESTOR ALERT: Investors With Large Losses in Verve Therapeutics, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights
September 03, 2024
From
Bernstein Liebhard LLP
Via
GlobeNewswire
VERV SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Verve Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
September 01, 2024
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Verve Therapeutics
August 29, 2024
From
Faruqi & Faruqi LLP
Via
GlobeNewswire
VERV Investors Have Opportunity to Lead Verve Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
August 29, 2024
From
The Schall Law Firm
Via
Business Wire
VERVE ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Verve Therapeutics, Inc. and Encourages Investors to Contact the Firm
August 28, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
Stockholder Notice: Robbins LLP Informs Stockholders of the Class Action Filed Against Verve Therapeutics, Inc.
August 28, 2024
From
Robbins LLP
Via
GlobeNewswire
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Verve Therapeutics
August 27, 2024
From
Faruqi & Faruqi, LLP
Via
Business Wire
EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit on Behalf of Verve Therapeutics, Inc. – VERV
August 27, 2024
From
Rosen Law Firm
Via
Business Wire
10 Health Care Stocks Whale Activity In Today's Session
↗
August 19, 2024
Via
Benzinga
VERV Stock Earnings: Verve Therapeutics Beats EPS, Beats Revenue for Q2 2024
↗
August 08, 2024
VERV stock results show that Verve Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via
InvestorPlace
Verve Therapeutics Announces Pipeline Progress and Reports Second Quarter 2024 Financial Results
August 08, 2024
From
Verve Therapeutics
Via
GlobeNewswire
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
August 02, 2024
From
Verve Therapeutics
Via
GlobeNewswire
What The Quest For New Cholesterol Treatments Means For Novartis, Merck — And Patients
↗
July 05, 2024
A number of companies are working on new drugs for high lipids, including cholesterol and triglycerides.
Via
Investor's Business Daily
Cathie Wood's Ark Invest Dumps Another $3.25M Worth Of Tesla Shares Amid Searing Q2 Deliveries Rally
↗
July 03, 2024
Via
Benzinga
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
July 01, 2024
From
Verve Therapeutics
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
...
12
13
Next >
